Continuous Glucose Monitoring in T2D Basal Insulin Users: The MOBILE Study
University of North Carolina at Chapel Hill
18 - 99 years
Adult T2D patients followed by a primary care physician, who are currently on basal insulin therapy with or without oral anti-diabetic therapy and/or GLP-1 analogue injections and who are sub-optimally controlled. Participants will be recruited from within the network or the referral base of the research site.